{
    "Trade/Device Name(s)": [
        "Signos Glucose Monitoring System"
    ],
    "Submitter Information": "Signos, Inc.",
    "510(k) Number": "K250106",
    "Predicate Device Reference 510(k) Number(s)": [
        "K234070"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "SAF"
    ],
    "Summary Letter Date": "January 13, 2025",
    "Summary Letter Received Date": "January 15, 2025",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 862.1355"
    ],
    "Regulation Name(s)": [
        "Integrated Continuous Glucose Monitoring System"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Interstitial fluid"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Over-the-counter interoperable continuous glucose monitor (iCGM)",
        "Mobile device application (Android or iOS)"
    ],
    "Method(s)/Technology(ies)": [
        "Amperometric measurement via glucose oxidase reaction (performed by iCGM)",
        "Bluetooth data transmission",
        "Mobile application data display"
    ],
    "Methodologies": [
        "Continuous glucose monitoring",
        "Mobile health data visualization"
    ],
    "Submission Type(s)": [
        "Software",
        "Accessory"
    ],
    "Document Summary": "FDA 510(k) summary for Signos Glucose Monitoring System mobile app displaying iCGM glucose readings for non-insulin users age 18+",
    "Indications for Use Summary": "Intended for OTC use as a mobile application paired with an iCGM to continuously measure, record, analyze, and display glucose levels in adults not on insulin, aiding detection and understanding of glycemic status and lifestyle impact, not for independent medical decision-making.",
    "fda_folder": "Clinical Chemistry"
}